Edwards Lifesciences Corporation (EW)
| Market Cap | 48.22B |
| Revenue (ttm) | 5.88B |
| Net Income (ttm) | 1.37B |
| Shares Out | 580.30M |
| EPS (ttm) | 2.33 |
| PE Ratio | 35.67 |
| Forward PE | 30.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,290,319 |
| Open | 83.32 |
| Previous Close | 83.84 |
| Day's Range | 81.26 - 83.60 |
| 52-Week Range | 65.94 - 87.89 |
| Beta | 0.95 |
| Analysts | Buy |
| Price Target | 96.37 (+15.97%) |
| Earnings Date | Feb 10, 2026 |
About EW
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solution... [Read more]
Financial Performance
In 2024, Edwards Lifesciences's revenue was $5.44 billion, an increase of 8.57% compared to the previous year's $5.01 billion. Earnings were $4.17 billion, an increase of 197.68%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for EW stock is "Buy." The 12-month stock price target is $96.37, which is an increase of 15.97% from the latest price.
News
Edwards Lifesciences Corporation (EW) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Edwards Lifesciences Corporation (EW) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Edwards Comments on JenaValve Acquisition
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission...
FTC wins ruling blocking Edwards Lifesciences' acquisition of JenaValve
The U.S. Federal Trade Commission won a ruling on Friday blocking Edwards Lifesciences Corp's acquisition of Jenavalve Technology Inc, court records showed.
HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investi...
FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the company's SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal appr...
Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026. Bernard Zovighian, c...
Edwards Lifesciences Corporation (EW) Analyst/Investor Day Transcript
Edwards Lifesciences Corporation (EW) Analyst/Investor Day Transcript
Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with moment...
Top small-cap plays for 2026
The Investment Committee debates their top small- and mid-cap names for 2026.
Artisan Global Discovery Fund: Q3 Delivers Strong Results Amid Trimming And Exits
The portfolio generated a modestly positive absolute return in Q3, but it trailed the MSCI All Country World Small Mid Index. The Q3 underperformance was driven by stock selection in the IT, financial...
Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease
NEW ORLEANS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced its founding sponsorship of the American Heart Association's Heart Valve Initiative, a national effort to improve care and...
Edwards Lifesciences Corporation (EW) Q3 2025 Earnings Call Transcript
Edwards Lifesciences Corporation ( EW) Q3 2025 Earnings Call October 30, 2025 5:00 PM EDT Company Participants Mark Wilterding - Vice President of Investor Relations Bernard Zovighian - CEO & Directo...
Edwards Lifesciences beats quarterly estimates on strength in heart devices
Edwards Lifesciences beat Wall Street estimates for third-quarter results on Thursday, driven by strong demand for its artificial heart valves and other medical devices, with shares rising about 3% in...
Edwards Lifesciences CFO Scott Ullem to step down by mid-2026
Edwards Lifesciences said on Thursday its Chief Financial Officer Scott Ullem will step down by mid-2026 and remain in an advisory role after a successor is named.
Edwards Lifesciences Announces CFO Transition Plan
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that Scott Ullem, the company's chief financial officer, has decided to transition from his role by midyear 2026. While...
Edwards Lifesciences Reports Third Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025. Recent Highlights Q3 sales grew 14.7% to $1.55 billion, or 1...
Halper Sadeh LLC Encourages Edwards Lifesciences Corporation Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciar...
EW Investor News: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edw...
Successful Patient Outcomes Demonstrated With Edwards' SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data...
Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data...
Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2025 after the market closes on Thursday October 30, 2025, ...
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation - EW
NEW YORK , Oct. 22, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lif...
EW Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences...
Edwards Lifesciences: Inflection Incoming, But When?
Edwards Lifesciences Corporation remains a market leader in transcatheter heart valve technologies, with strong secular tailwinds and consistent revenue growth. EW's TMTT segment is the fastest-growin...
Updated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care
MADRID--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) welcomes the updated ESC/EACTS guidelines for valvular heart disease, which establish a simplified care pathway for all severe aortic stenosis ...